Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL

Table 3

Sensitivity and specificity of three biomarkers with efficacy in predicting prostate cancer in patients with PSA 4–10 ng/mL.

—	Criterion	Sensitivity	95% CI	Specificity	95% CI	+LR	−LR	+PV	−PV
PCA3	23.5	97.0	84.2–99.9	41.6	31.2–52.5	1.7	0.1	38.1	97.4
	30.4	90.9	75.7–98.1	43.8	33.3–54.7	1.6	0.2	37.5	92.9
	35.4	81.8	64.5–93.0	46.1	35.4–57.0	1.5	0.4	36.0	87.2
	214.3	27.3	13.3–45.5	89.9	81.7–95.3	2.7	0.8	50.0	76.9
PSGR	24.2	90.9	75.7–98.1	20.2	12.4–30.1	1.1	0.5	29.7	85.7
	93.0	81.8	64.5–93.0	49.4	38.7–60.2	1.6	0.4	37.5	88.0
	623.3	12.1	3.4–28.2	96.6	90.5–99.3	3.6	0.9	57.1	74.8
MALAT-1	32.8	90.9	75.7–98.1	25.8	17.1–36.2	1.2	0.4	31.3	88.5
	109.6	72.7	54.5–86.7	60.7	49.7–70.9	1.9	0.5	40.7	85.7
	156.5	54.6	36.4–71.9	78.7	68.7–86.6	2.6	0.6	48.6	82.4
PSA	9.6	90.9	75.7–98.1	11.2	5.5–19.7	1.02	0.81	27.5	76.9
	7.95	72.7	54.5–86.7	39.3	29.1–50.3	1.20	0.69	30.8	79.5
	5.1	18.18	7.0–35.5	91.0	83.1–96.0	2.02	0.90	42.9	75.0
% fPSA	21.9	90.9	75.7–98.1	28.1	19.1–38.6	1.26	0.32	31.9	89.3
	23.2	100.0	89.4-100.0	24.7	16.2–35.0	1.33	0.00	33.0	100.0
	9.1	21.2	9.0–38.9	89.9	81.7–95.3	2.10	0.88	43.7	75.5

Indicating the cutoff value of the Youden index. PA: predictive accuracy; +LR: positive likelihood ratio; −LR: negative likelihood ratio; +PV: positive predicted value; −PV: negative predicted value.